Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 27;397(10280):1178-1181.
doi: 10.1016/S0140-6736(21)00502-X. Epub 2021 Feb 25.

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Maria Prendecki  1 , Candice Clarke  2 , Jonathan Brown  3 , Alison Cox  4 , Sarah Gleeson  5 , Mary Guckian  4 , Paul Randell  4 , Alessia Dalla Pria  6 , Liz Lightstone  2 , Xiao-Ning Xu  3 , Wendy Barclay  3 , Stephen P McAdoo  2 , Peter Kelleher  7 , Michelle Willicombe  2
Affiliations

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Maria Prendecki et al. Lancet. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Immunological responses to a single dose of BNT162b2 mRNA vaccine (A) Anti-S antibody titres 21–25 days after vaccination in individuals who were infection-naïve or had evidence of previous natural infection. Datapoints with open circles represent five individuals who, despite a negative serological test at baseline, were identified as having previous infection due to reactivity to non-spike peptides on ELISpot testing post-vaccination (which could not have been induced by vaccine alone). Dotted line indicates median anti-spike titre in a cohort of health-care workers 2–8 weeks after PCR-confirmed natural infection with SARS-CoV-2 (n=23, IQR 463–3621). (B) Correlation of post-vaccination anti-spike titre with age in infection-naïve participants. (C) SARS-CoV-2 live virus neutralising antibody titres in the eight individuals with paired results available (n=4 infection-naïve, n=4 with previous natural infection. (D) SARS-CoV-2 live virus neutralising antibody titres post-vaccination in infection-naïve individuals and individuals with previous infection. (E) T-cell responses to SARS-CoV-2 peptide pools post-vaccination in infection-naïve individuals and individuals with previous infection. Peptide pool 1 and peptide pool 2 contain spike protein peptides S1 and S2. Dotted lines indicate mean plus 3 standard deviation for each peptide pool calculated from infection naïve, unvaccinated individuals (48, 43, 26, 33, and 26 SFU/106 PBMC for peptide pools 1–5 respectively). (F) T-cell responses to spike protein peptides of SARS-CoV-2 post-vaccination in infection-naïve and previously infected participants. Inset shows example of ELISpot for an infection-naïve and a previously infected individual for the 2 spike peptide wells. Dotted line indicates mean plus 3 standard deviation for spike peptide pool reactivity calculated from infection naïve, unvaccinated individuals. All data are median with IQR. Statistical analysis was by Kruskall-Wallis test with Dunns' post-hoc correction (A), Spearman rank correlation (B) and Mann-Whitney test (D, F). SFU=spot forming unit. PBMC=peripheral blood mononuclear cells. NT50= neutralisation titres that achieved 50% neutralisation.
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New Eng J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Walsh EE, Frenck RW, Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. New Eng J Med. 2020;383:2439–2450. - PMC - PubMed
    1. Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nature Med. 2020;27:270–278. - PubMed
    1. Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New Eng J Med. 2021;384:403–416. - PMC - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed

Publication types